Aprogen Biologics Inc. (KRX:003060)
594.00
+11.00 (1.89%)
Nov 6, 2025, 1:39 PM KST
Aprogen Biologics Revenue
Aprogen Biologics had revenue of 14.90B KRW in the quarter ending June 30, 2025, a decrease of -1.94%. This brings the company's revenue in the last twelve months to 68.32B, down -7.21% year-over-year. In the year 2024, Aprogen Biologics had annual revenue of 67.38B, down -22.88%.
Revenue (ttm)
68.32B
Revenue Growth
-7.21%
P/S Ratio
1.69
Revenue / Employee
174.74M
Employees
391
Market Cap
115.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 67.38B | -19.99B | -22.88% |
| Dec 31, 2023 | 87.36B | 22.17B | 34.01% |
| Dec 31, 2022 | 65.19B | 8.71B | 15.42% |
| Dec 31, 2021 | 56.48B | 3.16B | 5.93% |
| Dec 31, 2020 | 53.32B | 2.42B | 4.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |